Life Edit Therapeutics
Alexandra Crawley is a co-founder and scientist at Life Edit Therapeutics, where responsibilities include leading bioinformatic and computational biology pipelines and driving gene discovery efforts for novel genome editing tools. With experience as a Bioinformatics Lead, Alexandra has developed gene discovery pipelines to identify CRISPR-based genome editing systems and established software for genetic targeting and evaluation across various organisms. Prior to Life Edit, Alexandra served as a Research Assistant at North Carolina State University, investigating CRISPR-Cas systems and teaching in related subjects, and also completed a Bioinformatics Internship at AgBiome focusing on gene discovery pipelines. Alexandra holds a PhD in Functional Genomics and an MS in Food Science from North Carolina State University, as well as a BSA in Food Science and Technology from The University of Georgia.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.